Clinical Trials Logo

Clinical Trial Summary

According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05070598
Study type Interventional
Source Shengjing Hospital
Contact Nan Zhang, doctor
Phone 18940253560
Email [email protected]
Status Recruiting
Phase Phase 2
Start date September 7, 2021
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04082364 - Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3
Recruiting NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT04520295 - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT04450732 - Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Phase 1
Recruiting NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Recruiting NCT04650451 - Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors Phase 1
Active, not recruiting NCT03650348 - PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Phase 1
Completed NCT04920747 - Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients